Business
Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board
Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board.
About this update from Oncology Pharma Inc.
[{"type":"text","content":"\n SAN FRANCISCO, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the Scientific Advisory Board. Dr. Henry Smith has over 50 years’ experience in Healthcare.  Dr. Smith has worked to develop novel technologies to serve the healthcare industry, including one of the first CEA (Carcinoma Embryonic Antigen) tests for detecting cancer.  In 1966, Dr. Smith published the first report that normal lymphocytes had an innate immunity to destroy cancer cells.  He is the co-founder of several biotech companies, and has maintained a keen interest in developing a variety of immunological methods to diagnose and treat cancer throughout his career.  Dr. Smith has a Ph.D in Medical Immunology from the University of Leeds, England. Oncology Pharma is excited to have Dr. Smith’s guidance in steering its advisory board as the Company grows and takes advantage of its licensed technologies. In order to focus on its near-term strategic goals, the Company has decided to discontinue pursuit of a license agreement with Kalos Therapeutics at this time. ABOUT ONCOLOGY PHARMA, INC. ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the \"Company\") is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare. ABOUT NANOSMART PHARMACEUTICALS, INC. NanoSmart® Pharmaceuticals is a privately-held California corporation that is developing nanoparticle drug delivery platforms that utilize anti-nuclear antibody (ANA) to target existing drug therapies to areas of necrosis present in virtually all solid cancer tumors. FORWARD-LOOKING STATEMENTS Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benef...